Bertrand Pourroy

1.2k total citations
47 papers, 823 citations indexed

About

Bertrand Pourroy is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bertrand Pourroy has authored 47 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bertrand Pourroy's work include Safe Handling of Antineoplastic Drugs (7 papers), Pharmaceutical studies and practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Bertrand Pourroy is often cited by papers focused on Safe Handling of Antineoplastic Drugs (7 papers), Pharmaceutical studies and practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Bertrand Pourroy collaborates with scholars based in France, United States and Zambia. Bertrand Pourroy's co-authors include Diane Braguer, Manon Carré, Claudette Briand, Nicolás André, Eddy Pasquier, Laurence Camoin‐Jau, Hervé Kovacic, Gaël Brasseur, Joseph Ciccolini and Bruno Lacarelle and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Scientific Reports.

In The Last Decade

Bertrand Pourroy

44 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bertrand Pourroy France 17 331 294 98 84 78 47 823
Rosa Lerose Italy 17 406 1.2× 360 1.2× 107 1.1× 80 1.0× 227 2.9× 34 1.1k
Dale Vimalachandran United Kingdom 18 332 1.0× 380 1.3× 128 1.3× 60 0.7× 122 1.6× 69 931
Christopher P. Mill United States 25 783 2.4× 252 0.9× 84 0.9× 64 0.8× 120 1.5× 82 1.8k
Orla McNally Australia 17 303 0.9× 346 1.2× 139 1.4× 31 0.4× 117 1.5× 65 1.3k
Suzy Lockwood United States 9 376 1.1× 330 1.1× 239 2.4× 31 0.4× 77 1.0× 16 994
Nirmala Chandralega Kampan Malaysia 14 249 0.8× 241 0.8× 111 1.1× 25 0.3× 70 0.9× 46 906
Sandra Kurtin United States 16 303 0.9× 432 1.5× 44 0.4× 28 0.3× 109 1.4× 78 884
Amit Garg United States 18 325 1.0× 372 1.3× 40 0.4× 63 0.8× 153 2.0× 39 1.1k
Chih‐Fen Huang Taiwan 21 539 1.6× 204 0.7× 155 1.6× 55 0.7× 121 1.6× 55 1.3k
Radoslav Chekerov Germany 20 327 1.0× 413 1.4× 208 2.1× 34 0.4× 100 1.3× 105 1.3k

Countries citing papers authored by Bertrand Pourroy

Since Specialization
Citations

This map shows the geographic impact of Bertrand Pourroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Pourroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Pourroy more than expected).

Fields of papers citing papers by Bertrand Pourroy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Pourroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Pourroy. The network helps show where Bertrand Pourroy may publish in the future.

Co-authorship network of co-authors of Bertrand Pourroy

This figure shows the co-authorship network connecting the top 25 collaborators of Bertrand Pourroy. A scholar is included among the top collaborators of Bertrand Pourroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertrand Pourroy. Bertrand Pourroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pourroy, Bertrand, et al.. (2025). Investigator‐Initiated Clinical Pharmacokinetic Studies in Resource‐Limited Settings: Minimal Requirements and Practical Guidance. The Journal of Clinical Pharmacology. 65(6). 675–687. 1 indexed citations
2.
Pourroy, Bertrand, et al.. (2025). The pharmaceutical circuit of Advanced Therapy Medicinal Products—guidelines of the French Society for Oncology Pharmacy. Cytotherapy. 27(8). 1023–1030. 1 indexed citations
3.
Ranchon, Florence, Florian Slimano, Isabelle Borget, et al.. (2025). Oncology pharmacy practice: Key insights, challenges, and perspectives – A position paper from the French Society for Oncology Pharmacy (SFPO). Annales Pharmaceutiques Françaises. 83(6). 1040–1052.
4.
Auvity, Sylvain, et al.. (2024). Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated. Frontiers in Medicine. 11. 1324602–1324602. 3 indexed citations
5.
Auvity, Sylvain, et al.. (2024). European Association of Hospital Pharmacists (EAHP) guidance on the pharmacy handling of in vivo gene therapy medicinal products. European Journal of Hospital Pharmacy. 31(5). 390–402. 3 indexed citations
6.
Pourroy, Bertrand, et al.. (2023). Circuit pharmaceutique du médicament de thérapie innovante (MTI) en France : état des lieux et perspectives. Annales Pharmaceutiques Françaises. 81(6). 1038–1053. 4 indexed citations
7.
Houédé, Nadine, Cécile Flahault, Marine Gross‐Goupil, et al.. (2022). Cancer de la vessie localement avancé ou métastatique : identification des freins et leviers du parcours des patients en France. Bulletin du Cancer. 109(9). 925–937.
8.
Slimano, Florian, Jérémie Zerbit, Audrey Thomas‐Schoemann, et al.. (2020). Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). Cancer Treatment Reviews. 88. 102063–102063. 33 indexed citations
9.
Venton, Geoffroy, Pierre Suchon, Cédric Mercier, et al.. (2019). Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. European Journal Of Haematology. 103(4). 385–392.
10.
11.
Rochigneux, Philippe, N. Schleinitz, Mikaël Ebbo, et al.. (2018). Acute myositis. Anti-Cancer Drugs. 29(5). 477–481. 13 indexed citations
12.
Rodallec, Anne, Sarah Giacometti, Manon Carré, et al.. (2018). From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. International Journal of Nanomedicine. Volume 13. 6677–6688. 26 indexed citations
13.
Bennis, Youssef, et al.. (2015). Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. International Journal of Pharmaceutics. 495(2). 956–962. 3 indexed citations
14.
Pourroy, Bertrand, et al.. (2015). Pertinence des prescriptions « hors AMM/RTU » des molécules onéreuses dans un hôpital universitaire. Therapies. 70(5). 385–402. 2 indexed citations
15.
Bennis, Youssef, et al.. (2014). Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?. International Journal of Clinical Pharmacy. 36(2). 420–429. 26 indexed citations
16.
Pourroy, Bertrand, Angélique Rome, Carole Coze, et al.. (2006). Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma. Anti-Cancer Drugs. 17(10). 1231–1234. 6 indexed citations
17.
Salas, Sébastien, Cédric Mercier, Joseph Ciccolini, et al.. (2006). Therapeutic Drug Monitoring for Dose Individualization of Cisplatin in Testicular Cancer Patients Based Upon Total Platinum Measurement in Plasma. Therapeutic Drug Monitoring. 28(4). 532–539. 33 indexed citations
18.
Bourgarel‐Rey, Véronique, et al.. (2006). Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anti-Cancer Drugs. 17(2). 181–187. 22 indexed citations
19.
Ries, Pauline, Laëtitia Dahan, Philippe Grandval, et al.. (2005). Neurotoxicité de l’oxaliplatine : trois cas d’exacerbation post-opératoire. Gastroentérologie Clinique et Biologique. 29(4). 461–464. 4 indexed citations
20.
André, Nicolás, Manon Carré, Gaël Brasseur, et al.. (2002). Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Letters. 532(1-2). 256–260. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosa Lerose Breakdown of academic impact, for papers by Dale Vimalachandran Breakdown of academic impact, for papers by Christopher P. Mill Breakdown of academic impact, for papers by Orla McNally Breakdown of academic impact, for papers by Suzy Lockwood Breakdown of academic impact, for papers by Nirmala Chandralega Kampan Breakdown of academic impact, for papers by Sandra Kurtin Breakdown of academic impact, for papers by Amit Garg Breakdown of academic impact, for papers by Chih‐Fen Huang Breakdown of academic impact, for papers by Radoslav Chekerov
Rankless by CCL
2026